Alnylam: Patisiran Shows Improvement Of Cardiomyopathy In APOLLO Phase 3 Study

Shutterstock photo

(RTTNews.com) - Alnylam Pharmaceuticals, Inc. ( ALNY ) reported new results from the APOLLO Phase 3 study of patisiran, an investigational, RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis. The company said the data highlighted that treatment with patisiran was associated with significant improvements in measures of cardiomyopathy, the leading cause of death in patients with hATTR amyloidosis, relative to placebo. Patisiran was also associated with a favorable effect on gait speed in the cardiac subpopulation, relative to placebo. Furthermore, patisiran treatment led to a significant reduction in levels of a cardiac stress biomarker, NT-proBNP, relative to placebo at 9 and 18 months.

Alnylam Pharma also reported new data from the Phase 1 study of ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of ATTR amyloidosis. The company said single doses of ALN-TTRsc02 demonstrated robust TTR knockdown (mean maximum up to 97 percent) maintained over 320 days.

Read the original article on RTTNews (http://www.rttnews.com/2876961/alnylam-patisiran-shows-improvement-of-cardiomyopathy-in-apollo-phase-3-study.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: World Markets , Stocks , Technology
Referenced Symbols: ALNY

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?